Back to results
US 2022/0018845 A1Published application
Articles and methods directed to personalized therapy of cancer
AssigneesHesperix SA, The Scripps Research Institute
InventorsAlexey Vyacheslavovich Stepanov, Dmitry Dmitrievich Genkin, Alexander Gabibovich Gabibov, Richard A. Lerner, Alexey Anatolievich Belogurov, Jia Xie
Life of this patent
Estimating the term…
Abstract
Described are methods for providing personalized medicine for the treatment of B cell malignancies including lymphoma. The methods make use of Chimeric Antigen Receptor (CAR) technology.
Claims11
A method of treating lymphoma in a human subject comprising:
- identifying a unique B cell receptor expressed in clonally related malignant lymphoma cells of the subject;
- modifying T cells to co-express the unique B cell receptor or a fragment thereof with a library of CARs comprising putative ligands of the unique B cell receptor, wherein the unique B cell receptor or fragment thereof and the putative ligands are expressed on the surface of the modified in T cells;
- detecting binding of said unique B cell receptor to a putative ligand of the unique B cell receptor, thereby identifying a ligand of the unique B cell receptor ligand;
- and
- administering to the subject a therapeutically effective amount of the ligand of the unique B cell receptor coupled to an immunotherapeutic agent.
2 more elements
The method of claim 5, wherein identifying activation of the T cell comprises measuring expression of CD69 or CD25.
Dependencies are inferred from the claim text.